Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge-Reply

Charles Dolladille^{1

2}, Angélique Da-Silva³, Joachim Alexandre^{1

2}

Affiliations

¹ PICARO Cardio-oncology Program, Signalisation, Électrophysiologie et Imagerie des Lésions d'Ischémie-Reperfusion Myocardique, Centre Hospitalier Universitaire (CHU) de Caen Normandie, Department of Pharmacology, EA 4650, Normandie University, University of Caen Normandy, Caen, France.
² CHU de Caen Normandie, Department of Pharmacology, Caen, France.
³ Centre Francois Baclesse Centre de Lutte Contre le Cancer (Cancer Centre), Caen, France.

Comment

Charles Dolladille et al. JAMA Oncol. 2020.

. 2020 Nov 1;6(11):1814-1815.

doi: 10.1001/jamaoncol.2020.3960.

Charles Dolladille^{1

2}, Angélique Da-Silva³, Joachim Alexandre^{1

2}

¹ PICARO Cardio-oncology Program, Signalisation, Électrophysiologie et Imagerie des Lésions d'Ischémie-Reperfusion Myocardique, Centre Hospitalier Universitaire (CHU) de Caen Normandie, Department of Pharmacology, EA 4650, Normandie University, University of Caen Normandy, Caen, France.
² CHU de Caen Normandie, Department of Pharmacology, Caen, France.
³ Centre Francois Baclesse Centre de Lutte Contre le Cancer (Cancer Centre), Caen, France.

No abstract available

Comment on

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.
Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, Fedrizzi S, Chrétien B, Da-Silva A, Plane AF, Legallois D, Milliez PU, Lelong-Boulouard V, Alexandre J. Dolladille C, et al. JAMA Oncol. 2020 Jun 1;6(6):865-871. doi: 10.1001/jamaoncol.2020.0726. JAMA Oncol. 2020. PMID: 32297899 Free PMC article.
Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge.
Zheng SY, Duan H, Cui HJ. Zheng SY, et al. JAMA Oncol. 2020 Nov 1;6(11):1813. doi: 10.1001/jamaoncol.2020.3946. JAMA Oncol. 2020. PMID: 32970125 No abstract available.
Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge.
Liu J, Yu J, Meng X. Liu J, et al. JAMA Oncol. 2020 Nov 1;6(11):1813-1814. doi: 10.1001/jamaoncol.2020.3955. JAMA Oncol. 2020. PMID: 32970130 No abstract available.